PE20231640A1 - Mutaciones en regiones constantes de anticuerpos felinos - Google Patents

Mutaciones en regiones constantes de anticuerpos felinos

Info

Publication number
PE20231640A1
PE20231640A1 PE2023001870A PE2023001870A PE20231640A1 PE 20231640 A1 PE20231640 A1 PE 20231640A1 PE 2023001870 A PE2023001870 A PE 2023001870A PE 2023001870 A PE2023001870 A PE 2023001870A PE 20231640 A1 PE20231640 A1 PE 20231640A1
Authority
PE
Peru
Prior art keywords
mutations
constant regions
feline
feline antibodies
antibodies
Prior art date
Application number
PE2023001870A
Other languages
English (en)
Inventor
Henry Luis Campos
Sandra Ann Marie Lightle
Lisa Marie Bergeron
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of PE20231640A1 publication Critical patent/PE20231640A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invencion se refiere generalmente a variantes de anticuerpos felinos y usos de estos. Especificamente, la invencion se refiere a mutaciones en la region constante de anticuerpo felino para mejorar diversas caracteristicas.
PE2023001870A 2020-12-18 2021-12-17 Mutaciones en regiones constantes de anticuerpos felinos PE20231640A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063127313P 2020-12-18 2020-12-18
PCT/US2021/064097 WO2022133252A1 (en) 2020-12-18 2021-12-17 Mutations in feline antibody constant regions

Publications (1)

Publication Number Publication Date
PE20231640A1 true PE20231640A1 (es) 2023-10-16

Family

ID=79730576

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001870A PE20231640A1 (es) 2020-12-18 2021-12-17 Mutaciones en regiones constantes de anticuerpos felinos

Country Status (14)

Country Link
EP (1) EP4263596A1 (es)
JP (1) JP2024503212A (es)
KR (1) KR20230121056A (es)
CN (1) CN116547298A (es)
AU (1) AU2021400322A1 (es)
CA (1) CA3202074A1 (es)
CL (2) CL2023001781A1 (es)
CO (1) CO2023007829A2 (es)
EC (1) ECSP23044286A (es)
IL (1) IL303732A (es)
MX (1) MX2023006898A (es)
PE (1) PE20231640A1 (es)
TW (1) TW202233687A (es)
WO (1) WO2022133252A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024050491A2 (en) * 2022-09-02 2024-03-07 Zoetis Services Llc Porcine antibody mutants
US20240209062A1 (en) * 2022-12-27 2024-06-27 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
WO2024155982A2 (en) * 2023-01-20 2024-07-25 Invetx, Inc. Bispecific binding agents for use in companion animals

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
KR20070057839A (ko) 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
WO2006104989A2 (en) * 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
KR20210110563A (ko) * 2018-10-18 2021-09-08 킨드레드 바이오사이언시스, 인코포레이티드 수의학적 용도를 위한 신생아 fc 수용체(fcrn)에 변경된 결합을 갖는 fc 변이체
WO2020116560A1 (ja) * 2018-12-05 2020-06-11 株式会社バイカ・セラピュティクス 抗体のＦｃ領域改変体

Also Published As

Publication number Publication date
MX2023006898A (es) 2023-06-26
CO2023007829A2 (es) 2023-07-21
CN116547298A (zh) 2023-08-04
KR20230121056A (ko) 2023-08-17
CA3202074A1 (en) 2022-06-23
AU2021400322A1 (en) 2023-06-22
ECSP23044286A (es) 2023-07-31
CL2023001781A1 (es) 2023-12-22
IL303732A (en) 2023-08-01
CL2024001519A1 (es) 2024-08-23
JP2024503212A (ja) 2024-01-25
EP4263596A1 (en) 2023-10-25
WO2022133252A1 (en) 2022-06-23
TW202233687A (zh) 2022-09-01

Similar Documents

Publication Publication Date Title
PE20231640A1 (es) Mutaciones en regiones constantes de anticuerpos felinos
CL2023003377A1 (es) Variantes de anticuerpos caninos
CL2023003376A1 (es) Variantes de anticuerpos felinos
ECSP23030271A (es) Variantes de anticuerpos caninos
CL2024001562A1 (es) Mutaciones en regiones constantes de anticuerpos caninos.
EA202092847A1 (ru) Антитела к cd3 и их применение
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
EA201891694A1 (ru) Фармацевтическая композиция, содержащая конструкты биспецифических антител
CO2023007146A2 (es) Variantes de anticuerpos bovinos
ECSP20025198A (es) Conjugados de fármaco-anticuerpo activable anti-cd71 y métodos de uso de estos
EA201991876A1 (ru) Антитела против фактора d и их применения
EA202190382A1 (ru) Фармацевтические составы на основе маскированных антител
PE20230259A1 (es) Anticuerpos anti-tgf-beta con selectividad de isoforma y metodos de uso
CL2021002710A1 (es) Anticuerpos biespecíficos
ECSP23030307A (es) Variantes de anticuerpos felinos
PE20240080A1 (es) Anticuerpos anti-hbv y metodos de uso
EA202091973A1 (ru) Конструкции слитых белков, содержащие анти-muc1 антитело и il-15
EA201992186A1 (ru) Антитела к par2 и пути их применения
TR202104726A2 (tr) Köfte form maki̇nasinda yeni̇li̇k
MX2024006208A (es) Anticuerpo anti-trem2 y usos del mismo.
AR116101A1 (es) Proteína de unión al antígeno anti-steap1
EA201991614A1 (ru) СПЕЦИФИЧНЫЕ К ИЗОФОРМЕ, ПЕРМИССИВНЫЕ ПО ОТНОШЕНИЮ К КОНТЕКСТУ ИНГИБИТОРЫ TGFβ1 И ИХ ПРИМЕНЕНИЕ
HN2009001974A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentacion de anticuerpos, que se unen especificamente a cd154 y sus usos.